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Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Tumor dissemination to the
extra-hepatic region of the portal vein, lymph nodes, lungs or bones contributes to the high mortality seen in HCC;
yet, the molecular mechanisms responsible for HCC metastasis remain unclear. Prior studies have suggested a
potential link between accumulated cytoplasm-localized p16 and tumor progression. Here we report that p16
enhances metastasis-associated phenotypes in HCC cells – ectopic p16 expression increased cell migration in vitro,
and lung colonization after intravenous injection, whereas knockdown of endogenous p16 reduced cell migration.
Interestingly, analysis of p16 mutants indicated that the Cdk4 interaction domain is required for stimulation of HCC
cell migration; however, knockdown of Cdk4 and Cdk6 showed that these proteins are dispensable for this
phenomenon. Intriguingly, we found that in p16-positive HCC samples, p16 protein is predominantly localized in the
cytoplasm. In addition, we identified a potential role for nuclear-cytoplasmic shuttling in p16-stimulated migration,
consistent with the predominantly cytoplasmic localization of p16 in IHC-positive HCC samples. Finally, we
determined that p16-stimulated cell migration requires the Cdc42 GTPase. Our results demonstrate for the first time
a pro-migratory role for p16, and suggest a potential mechanism for the observed association between cytoplasmic
p16 and tumor progression in diverse tumor types.
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Introduction
An estimated 750,000 new cases of hepatocellular
carcinoma (HCC) are diagnosed each year, with a survival rate
of less than 5%, and an average survival of less than one year
after diagnosis [1]. HCC is usually associated with chronic
infection by the hepatitis B virus (HBV) or hepatitis C virus
(HCV), environmental carcinogens and alcohol consumption
[2,3]. Among the common genetic and epigenetic alterations
found in HCC are inactivating TP53 mutations, and inactivation
of the INK4A/ARF locus by deletion or promoter methylation
[4–6]. These findings suggest important roles for the p53,
p16Ink4a, and p14Arf tumor suppressors in HCC pathogenesis.
We have previously described a HCC mouse model induced
by the somatic and sporadic activation of oncogenes
specifically in the liver [7]. Our data demonstrated that liver-
specific Trp53 deletion induced the development of lung
metastases, the formation of which could be enhanced by
concomitant deletion of Ink4a/Arf [8]. Furthermore, we showed
that mouse HCC cell lines lacking both Trp53 and Ink4a/Arf
displayed increased migration and invasion abilities when
compared to a mouse HCC cell line with Trp53 deletion alone,
suggesting that the Ink4a/Arf locus may play a role in the
control of these processes [8].
The Ink4a/Arf locus encodes two distinct tumor suppressors
– the cyclin dependent kinase (Cdk) inhibitor p16, and a protein
translated from an alternative reading frame, Arf (p14 in human
and p19 in mouse) – that are involved in the Rb and p53
pathways, respectively [9–11]. In agreement, mice with specific
deletion of either Ink4a or Arf are tumor prone, but neither is as
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severely affected as animals lacking Ink4a/Arf, indicating that
Ink4a and Arf play critical and non-redundant roles in
suppressing malignancy [12]. We have previously shown that
p19 regulates HCC cell invasion [13], yet whether p16 plays a
similar role remained untested.
In approximately a third of human cancers, p16 is inactivated
by chromosomal losses, point mutation, and/or promoter
methylation [12,14]. Loss of p16 expression occurs frequently
in the most common human cancers and has been associated
with a poor prognosis [12]. Conversely, a growing body of data
suggests that up-regulation of p16 correlates with a more
aggressive phenotype in some types of tumors [15–19]. For
example, over-expression and aberrant cytoplasmic
localization of p16 in breast cancer is associated with
accelerated tumor proliferation and a more malignant
phenotype [15,16]. Therefore, elucidating whether p16
performs divergent functions during tumor initiation and tumor
progression is of great importance.
In this manuscript, we show that ectopic p16 expression
unexpectedly enhances HCC cell migration in transwell assays
and lung colonization after tail vein injection, while RNA
interference (RNAi)-mediated knockdown of p16 inhibits cell
migration. We further show that p16-enhanced cell migration is
dependent on its Cdk binding domain, and requires Cdc42.
Intriguingly, our data also suggest a potential role for nuclear-
cytoplasmic shuttling of p16 in this phenomenon. Collectively,
these data suggest a novel role for p16 in stimulating the
migration activity of hepatocellular carcinoma cells.
Materials and Methods
Cell lines
The MM189, BL322 and BL185 HCC cell lines have been
previous described [8,13]. HepG2 cells, purchased from
American Type Culture Collection, were cultured in Dulbecco’s
Modified Eagle Medium (DMEM, Invitrogen) supplemented with
10% fetal bovine serum (FBS, Biological Industries) and
antibiotics (Invitrogen).
Ethics Statement
All animal studies were performed in strict accordance with
the recommendations in the guidelines for the care and use of
Laboratory Animals of National Health Research Institutes,
Taiwan. The Institutional Animal Care and Use Committee
(IACUC) of National Health Research Institutes approved the
protocols (Protocol No:NHRI-IACUC-098055-A and NHRI-
IACUC-099102-A). Animals were housed with abundant food
and water. All efforts were made to minimize suffering.
Plasmids
All cDNA expression constructs were generated in either
pBabe-puro or pBabe-neo expression vectors (Addgene).
cDNA encoding wild type mouse p16 was generated by
reverse transcription and PCR amplification of RNA isolated
from BL185 HCC cells using the Superscript III first strand
synthesis system (Invitrogen) according to the manufacturer’s
protocol. cDNAs encoding p16 mutants were generated by site-
directed mutagenesis using PCR with mismatched annealing.
HIV rev NES or SV40 NLS tagged p16 constructs were
generated by PCR amplification using primers containing the
NES or NLS sequences. All primer sequences are listed in
Table S1. Expression constructs were transfected into the
packaging cell line 293G/P, in company with Pol/GAG and
pVSV-G plasmids (Clontech) using the Polyjet transfection
reagent (SignaGen lab). After 48 hr incubation, viral
supernatants were transferred on to target cells, and infected
cells cultured in the presence of either 8 µg/ml puromycin
(Calbiochem) or 0.5 mg/ml neomycin (G418, Biochrom AG).
RNAi-mediated depletion was achieved by infecting cells with
pLKO-based lentiviruses encoding short hairpin RNA (shRNA)
targeting the mRNA (National RNAi Core Facility, Academia
Sinica, Taiwan). Clones used are listed in the supplemental
materials. RNAi-mediated depletion of mouse p19 was
conducted by infecting target cells with MLP retroviral vectors
encoding a short hairpin RNA (shRNA) targeting Arf-specific
sequences (a gift from Dr. Scott W. Lowe, Cold Spring Harbor
Laboratory).
IP-Western blot analysis
Cell lysate was mixed with RIPA buffer lacking SDS and
deoxycholate in company with primary anti-p16 antibody
(Santa Cruz) and pre-washed Protein A/G beads (Calbiochem).
Following several washes, beads were denatured in sample
buffer and supernatant was saved for immunoblot analysis.
Immunoblotting
Immunoblotting was performed as previously described [13].
Primary antibodies used are listed File S1.
Analysis of GTPase activity
Endogenous small GTPase activity was determined using
glutathione S-transferase (GST) fusion proteins containing
either the p21-binding domain (PBD) of human p21-activated
protein kinase 1 (Pak1) (GST-PAK1) that interacts with active
forms of Cdc42 and Rac1, or the Rhotekin-binding domain
(RBD) that interacts with active Rho (GST-PAK1 and GST-
Rhotekin, are gifts from Dr. Lu-Hai Wang, National Health
Research Institutes, Taiwan) [20,21]. Briefly, cell lysate in
RIPA-buffer was incubated with pre-washed glutathione beads
(Sigma) bound with either GST-PAK1 or GST-Rhotekin. After
washing, boiling in sample buffer eluted bound proteins, and
the supernatant loaded on to SDS-PAGE. Immunoblotting was
performed with anti-Rho (05-778, Millipore), anti-Cdc42
(07-1466, Millipore) and anti-Rac1 (05-389, Millipore)
antibodies. GTPγS (Millipore) served as a positive control to
maintain the active forms of GTPases in the reaction. GST
detection by anti-GST antibody (sc-459, Santa Cruz) served as
a loading control. The protein intensity was measured and
quantified using ImageJ software.
Cell proliferation
Cell proliferation analysis was performed as previously
described [8]. Experiments were repeated at least three times.
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Soft agar assay
Soft agar assays were performed as previously described
[22]. The number of colonies larger than 25 µm in diameter
present within 20 microscopic fields was counted under a light
microscope. All experiments were performed in triplicate and
repeated a minimum of three times.
In vitro migration and invasion assays
Migration and invasion assays were performed as described
in our previous studies [13]. The number of migrated cells was
determined by counting the cell numbers in 5 fields/per insert at
100X magnification. The mean number of migrated cells was
determined by averaging the number of migrated cells in two
independent inserts. The relative migration activity was
determined by normalizing the mean number of migrated cells
in experimental cells to that of vector controls, with the
migration activity of the control cells set to 1. Invasion assays
were performed using transwells with matrigel coating (Becton
Dickinson). The number of invaded cells was determined by
counting the cell numbers in 5 fields/per insert at 100X
magnification. The mean number of invaded cells was
determined by averaging the number of invaded cells in two
independent inserts. The relative invasion activity was
determined by normalizing the mean number of invaded cells in
experimental cells to that of vector controls, with the invasion
activity of the control cells set to 1. Each experiment was
repeated at least three times. Data shown are from
representative experiments.
Immunofluorescence (IF)
IF was performed as described previously [13]. Primary
antibody used: anti-p16 (sc-1207, Santa Cruz).
Lung colonization assay
Lung colonization assay was conducted as described
previously [8]. After 25-28 days, the lungs were harvested for
paraffin embedding, sectioning, and histological examination
after H&E staining. 4-5 animals were included in each group.
The tumor area was calculated using ImageJ software.
Immunohistochemical staining of human hepatocellular
carcinomas
Tissue microarrays (TMAs) of resected cases of human
hepatocellular carcinomas were previously described [23].
Briefly, triplicate 0.6 mm cores of carcinomas and matched
non-neoplastic liver samples from 124 hepatocellular
carcinomas (18 fibrolamellar carcinomas and 106 conventional
hepatocellular carcinomas) were punched and embedded in
donor blocks. Immunohistochemical staining for p16 was
performed using a monoclonal p16 antibody, clone INK4A
(MTM Laboratories, Heidelberg, Germany), diluted 1:5, with
standard techniques on the Ventana Discovery XT (Ventana
Corporation, Tucson AZ) automated immunostainer. Samples
of gastric and endometrial adenocarcinomas known to
overexpress p16 were used as positive controls. The stains
were interpreted as positive if there was distinct cytoplasmic or
nuclear reactivity in the neoplastic cells, greater than any
background staining in the matched non-neoplastic liver, in
more than 20% of the cells within the different cores of tumor.
Cytoplasmic and nuclear staining were separately recorded.
Survival information for the patients was obtained from the
clinical records.
Statistical analysis
Statistical calculation was performed using student t test
(Graphpad software, San Diego, CA). Findings with a p-value
of less than 0.05 were considered statistically significant. *,
p<0.05; **, p<0.01; ***, p<0.001.
Results
p16 expression enhances HCC cell migration
Our previous studies suggested that the Ink4a/Arf locus
plays a key role in regulating HCC cell migration, invasion, and
metastasis [8,13]. Therefore, we ascertained whether loss of
p16 was required for cellular phenotypes associated with tumor
metastasis [15,16,24–26]. The murine HCC cell lines MM189
and BL322, which are deleted at both Trp53 and Ink4a/Arf,
were infected with a retroviral vector encoding mouse p16, or
empty vector as a control, and ectopic p16 expression
confirmed by immunoblot (Figure 1A). We observed that
MM189 and BL322 cells with ectopic p16 expression displayed
increased migration in a transwell assay when compared with
their corresponding controls (Figure 1A). To exclude potential
retroviral mutagenesis effects, the experiments were repeated
with at least two independent batches of infected cells and
similar results obtained. We additionally tested whether ectopic
expression of p16 similarly enhanced cell invasion. However,
while ectopic p16 enhanced cell migration in both low and high
passage MM189 cells, it induced cell invasion in high passage
cells, but not low passage cells (Figure S1A). We therefore
focused our studies on the characterization p16’s involvement
in HCC cell migration.
To confirm that p16-enhanced migration occurs in additional
mammalian cells, including human cells, the human
hepatoblastoma cell line HepG2 and the BL185 murine HCC
cell line that retain functional Ink4a/Arf, were infected with a
retroviral vector encoding mouse p16, or an empty vector
control, and ectopic p16 expression confirmed by immunoblot
(Figure 1B). Ectopic p16 increased cell migration in both
HepG2 and BL185 cells when compared with their
corresponding controls (Figure 1B), suggesting that p16
enhanced cell migration is not cell line- or species-specific.
To determine whether loss of p16 reduces HCC cell
migration, we infected the BL185 HCC cell line with viral
vectors encoding shRNAs against mouse p16 or p19 and
specific knockdown confirmed by immunoblot (Figure 1C).
Reduced p16 levels resulted in a dramatic decrease in
migration activity; however, consistent with our published data
[13], this reduction was not observed in BL185 cells with p19
knockdown (Figure 1C). Likewise, RNAi-mediated depletion of
p16 in HepG2 cells (Figure 1D) reduced migration activity in
that cell line (Figure 1D). Taken together, our data demonstrate
that expression of p16 is necessary and sufficient for enhanced
HCC cell migration.
p16 Induces HCC Cell Migration
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Figure 1.  p16 enhances HCC cell migration.  (A) Upper panel: Immunoblot confirming ectopic p16 expression in MM189 and
BL322 mouse HCC cells infected with either pBabe-puro retrovirus (Vector control, VC) or pBabe-puro retrovirus encoding wild type
p16 (p16). β-actin serves as a loading control. Lower panel: Migration activity of MM189 and BL322 cells expressing p16, and their
vector controls. Data are from a representative experiment performed in duplicate. Bar, SEM. (B) Upper panel: Immunoblot
detection of ectopic p16 protein in BL185 and HepG2 HCC cells. Lower panel: Migration activity of BL185 and HepG2 cells
expressing ectopic p16, and their vector controls. Data are from a representative experiment performed in duplicate. Bar, SEM. (C)
Upper panel: Immunoblot detection of specific knockdown of p16 and p19 in BL185 HCC cells. pLKO-GFP is the non-silencing
control for the p16-targeting shRNA. MLP-Luci is the non-silencing control for the p19-specific shRNA. Lower panel: Migration
activity of BL185 cells with p16- or p19-specific knockdown relative to their non-silencing controls. Data are from a representative
experiment performed in duplicate. Bar, SEM. (D) Left panel: Immunoblot detection of p16-specific knockdown in HepG2 cells
infected with lentiviral vectors encoding p16-targeting shRNA, or a non-silencing control pLKO-GFP. Right panel: Migration activity
of HepG2 cells with p16 knockdown relative to cells expressing the non-silencing control (pLKO-GFP). Data are from a
representative experiment performed in duplicate. Bar, SEM. *, p<0.05; **, p<0.01; ***, p<0.001.
doi: 10.1371/journal.pone.0069389.g001
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Analysis of pRb expression demonstrated that MM189 cells
do not express pRb, whereas HepG2 cells are pRb-positive
(Figure S1B). These data suggest that p16 induces cell
migration independent of pRb status. Consistent with this,
knockdown of pRb in HepG2 p16 cells (Figure S1C) did not
impact cell migration (Figure S1D).
p16 enhances the ability of HCC cells to colonize the
lungs
To ascertain whether the effect of p16 on HCC cell migration
correlated with an in vivo phenotype, we determined the ability
of MM189 cells with ectopic p16 expression, or empty vector
controls, to colonize the lungs after tail vein injection. We
observed that p16 re-expression led to increased colony
formation in the lungs (100% versus 25% for vector controls)
and a dramatic increase in tumor area (Figure 2A and 2B).
p16-expressing MM189 cells formed lung lesions with an
average area of 4.583 ± 1.505 mm2 compared with 0.0491 ±
0.0491 mm2 for controls (Figure 2B). Thus, p16 enhances the
ability of HCC cells to colonize the lungs in vivo.
We further asked whether p16 plays critical roles in other
tumor-associated phenotypes in HCC cells. Measurement of
cell proliferation in MM189 p16 versus MM189 vector control
cells (Figure 2C), and HepG2 p16 versus HepG2 control cells
(Figure S1E), demonstrated that p16 inhibits cell proliferation in
a pRb-dependent manner. Next, we determined whether p16
affected the ability of MM189 cells to undergo anchorage-
independent growth and found that p16 expression reduces
colony formation in soft agar (Figure 2D). Consistent with this
observation, RNAi-mediated knockdown of p16 in HepG2 cells
enhances soft agar colony formation (Figure S1F). Thus, while
p16 enhances HCC cell migration, it retains other classical
tumor suppressor functions in these cells. These data suggest
that p16 may regulate cell migration and cell cycle progression
through separate mechanisms.
Cdk4 and Cdk6 are dispensable for p16-enhanced
migration
p16 binds to Cdk4 and Cdk6 to inhibit phosphorylation of
pRb and regulate the progression of the cell cycle. To
investigate whether interaction with Cdk4 or Cdk6 is involved in
p16-enhanced migration, we generated several p16 mutants,
some originally identified in human tumors, introduced them
into MM189 cells by retroviral transduction, and confirmed
expression by immunoblotting with p16-specific antibodies
(Figure 3A). We next assessed the ability of the mutants to
bind to Cdk4 and Cdk6 in co-immunoprecipitation experiments,
and observed three classes of mutants: the D66N and D76V
mutants that fail to interact with both Cdk4 and Cdk6; the A12S
and E112K mutants that retain interaction with both Cdks; and
the R79L mutant that weakly binds Cdk6 but fails to interact
with Cdk4 (Figure 3B). We next tested representative mutants
for their effect on HCC cell migration. While the A12S mutant
induced migration as effectively as wild type p16 in MM189
cells, the D76V and R79L mutants failed to do so (Figure 3C).
Thus the Cdk4 binding region of p16 is required for its ability to
induce the migration of HCC cells.
To directly test the requirement for Cdk4 and Cdk6 in p16-
induced cell migration, we knocked down Cdk4 and Cdk6
expression in MM189 cells and confirmed knockdown by
immunoblot (Figure 3D). Reduced Cdk4 or Cdk6 levels did not
impair p16-mediated migration, suggesting that Cdk4 and Cdk6
are dispensable for p16-enhanced migration even though the
Cdk interaction domain is required (Figure 3E).
p16 is localized in the cytoplasm in human HCC
Prior studies suggested that accumulated cytoplasm-
localized p16 could be identified in certain tumor types and is
associated with tumor progression and poor prognosis [15,16].
Moreover, a survey of prior gene expression profiling studies in
Oncomine suggested a correlation between elevated CDKN2A
mRNA levels and increased tumor grade [24–27]. Therefore, to
determine whether aberrant cytoplasmic localization of p16
also occurs in hepatocellular carcinoma, we stained a tissue
microarray (TMA) containing human liver tumor samples. 124
tissue cores on the array could be evaluated. Of these, 18 were
fibrolamellar carcinomas, and 3 of these stained positive for
p16. Of the 106 HCC cases on the TMA, 90 did not display p16
staining above background (Figure 4C), whereas 16 cases
displayed detectable p16 staining (Figure 4D–F). In most cases
(12), the p16 staining was evident in 21-80% of the cancer
cells, whereas 4 samples displayed focal staining in less than
20% of cells. Interestingly, of the p16-positive HCCs, 15
displayed predominantly cytoplasmic staining (Figure 4D, E),
while only a single tumor displayed strong nuclear staining
(Figure 4F). Importantly, gastric (Figure 4A) and endometrial
(Figure 4B) carcinoma samples on the TMA displayed either
nuclear p16 staining or both nuclear and cytoplasmic staining,
suggesting that the cytoplasmic staining pattern observed in
the HCC samples is not artifactual. Immunohistochemical
staining of paired HCC and normal tissues demonstrated
cytoplasmic staining of p16 in the tumor but nuclear staining in
normal hepatocytes (arrows, Figure S2). Thus, p16 is
predominantly localized to the cytoplasm in HCC tissue.
Nuclear-cytoplasmic shuttling of p16 is required for
enhanced migration
Since our immunostaining data indicated that p16 was
localized predominantly within the cytoplasm in HCC tissues,
we ascertained the cellular localization of p16 in the HCC cell
lines used in our prior experiments. Endogenous p16, present
in BL185 cells, is predominantly localized within the nucleus
(Figure 5A). However, ectopically expressed p16 in this cell line
is distributed in both the nucleus and cytoplasm (Figure S3A).
Similarly, reintroduction of p16 into the Ink4a/Arf null MM189
HCC cell line resulted in localization of the ectopic protein
within the nucleus and cytoplasm (Figure 5A). Interestingly,
using leptomycin B mediated blockade of nuclear export, we
demonstrated that the ectopic p16 protein in MM189 cells
shuttles between the nucleus and cytoplasm through an active
transport process (Figure S3B). These data, coupled with the
identification of cytosol-localized p16 in tumor samples, raised
the possibility that the cytoplasmic localization of p16
contributes to its ability to induce migration in HCC cells.
However, p16 does not have a recognizable nuclear
p16 Induces HCC Cell Migration
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localization signal (NLS) or a nuclear export signal (NES).
Therefore, to test whether sub-cellular localization of p16
contributes to cell migration, we generated expression
constructs encoding p16 tagged with the HIV Rev NES at
either the C-terminus or both N- and C-termini, and constructs
encoding p16 tagged with the Simian Virus 40 T antigen NLS
at either the C-terminus or both N- and C-termini.
Immunoblotting confirmed the stability of the tagged proteins
Figure 2.  p16 enhances lung colonization by HCC cells.  (A) Representative lung fields of nude mice after the delivery, via tail
vein injection, of MM189 cells with ectopic p16 expression (MM189 p16) or vector controls (MM189 VC). The boxed area in the
upper panel is shown at higher magnification in the lower panel. (B) Quantification of the total area of the lung lesions in mice
injected with MM189 p16 or MM189 VC cells. Bar, SEM. (C) Representative cell proliferation assay for MM189 p16 and MM189 VC
cells. (D) Representative anchorage-independent growth assay for MM189 VC and MM189 p16 cells. Bar, SEM. *, p<0.05; **,
p<0.01; ***, p<0.001.
doi: 10.1371/journal.pone.0069389.g002
p16 Induces HCC Cell Migration
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(Figure 5B) and immunofluorescence staining confirmed their
restriction to the appropriate sub-cellular compartment (Figure
5A).
We additionally confirmed that the NLS- and NES-tagged
p16 proteins retained the ability to interact with Cdk4 and Cdk6
in co-IP experiments (Figure 5C). In transwell migration
assays, we found that cytosol-localized p16 failed to stimulate
Figure 3.  Cdk4 and Cdk6 are dispensable for p16-enhanced migration.  (A) Immunoblot detection of p16 mutants in MM189
cells. (B) IP-Western Blot detection of binding of p16 mutants to Cdk4 and Cdk6. (C) Migration activity of MM189 cells expressing
listed p16 mutants. Bar, SEM. (D) Immunoblot for Cdk4 or Cdk6 knockdown in MM189 p16 cells. (E) Migration activity of MM189
p16 cells with Cdk4 or Cdk6 knockdown relative to that of cells infected with a non-silencing control, pLKO-GFP. Bar, SEM. *,
p<0.05; **, p<0.01; ***, p<0.001.
doi: 10.1371/journal.pone.0069389.g003
p16 Induces HCC Cell Migration
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cell migration (Figure 5D). Interestingly, nuclear-restricted p16
likewise failed to induce cell migration in MM189 cells (Figure
5E). These data suggest that restriction of p16 to a specific
cellular compartment impairs its ability to stimulate HCC cell
migration, and further suggest that nuclear-cytoplasmic
shuttling of p16 plays an important role in p16-induced cell
migration in HCC cells.
Increased Cdc42 and Rac1 GTPase activity in p16-
enhanced migration
Tumor cell migration is often associated with the occurrence
of an epithelial-to-mesenchymal transition (EMT), and the
activation of the small GTPases Rho, Cdc42 and Rac1 [28,29].
We therefore determined whether any of these phenomena are
associated with p16-induced cell migration. Immunoblotting
showed that p16 expression in MM189 cells does not affect the
levels of epithelial proteins such as α-catenin and E-cadherin,
or mesenchymal markers, including N-cadherin and Vimentin
(Figure 6A). Further, p16 re-expression did not significantly
increase the level of EMT-related transcription factors, such as
Twist, Snail and Slug (Figure 6A). In contrast, our recently
published data demonstrated that Klf4 regulates an EMT in this
cell line [30]. Thus, p16-induced migration does not involve an
EMT.
Next, cell lysates were analyzed for evidence of activation of
small GTPases via the ability of GST-fused Pak1-PBD to
capture active Rac1 (Rac1-GTP) or Cdc42 (Cdc42-GTP)
molecules and GST-fused Rhotekin-RBD to capture active Rho
(Rho-GTP) molecules in a pull down assay [20,21]. As
compared to the vector control, expression of p16 resulted in
the robust induction of Cdc42-GTP and Rac1-GTP with 2.23-
and 1.89-fold increases, respectively, but reduced Rho-GTP
levels by almost 2-fold (Figure 6B and 6C), suggesting that the
balance of Cdc42, Rac1 and Rho proteins, mediates p16-
induced cell migration.
We next determined whether these small GTPases are
required for p16-mediated migration by targeting individual
GTPases with specific shRNAs. We found that knockdown of
Cdc42 strongly inhibited p16-mediated cell migration (Figure
7A, B), while depletion of Rac1 had only a negligible effect
(Figure 7C, D). By contrast, knockdown of RhoA enhanced
p16-mediated migration (Figure 7E, F). We observed similar
effects in cells treated with the Rho inhibitor Y27532 and a
Rac1 inhibitor (Figure S4A and B). These data indicate that
Cdc42 is a positive mediator of p16-induced HCC cell
migration, while RhoA inhibits this phenotype.
Discussion
INK4A encodes p16, an inhibitor of Cyclin D/Cdk complexes.
p16 acts to constrain Cdk-mediated phosphorylation of pRb,
thereby regulating transition through the G1 phase of the cell
cycle. Consistent with this function, p16 is a bona-fide tumor
suppressor and loss of p16 function is a common event in
human cancers [31–33]. However, emerging data have
suggested that overexpression and abnormal cytoplasmic
localization of p16 may correlate with tumor grade, tumor
progression and/or poor prognosis in multiple tumor types
including HCC [15–19,24–26,34]. These findings suggest that,
in certain contexts, p16 may potentially play pro-tumorigenic
roles as well; however, prior to our study, this had not been
experimentally demonstrated. While the antithesis of the
current view of p16 function, context-dependent pro- and anti-
tumorigenic functions have been demonstrated for several
Figure 4.  Human HCC samples display cytoplasmic localization of p16.  Control gastric (A) and endometrial (B) carcinoma
samples displaying nuclear and cytoplasmic staining for p16. (C–F) Representative images of HCC samples displaying different
levels and localization of p16 staining. Note the absence of nuclear staining in panels (D and E). All images are at 200X
magnification.
doi: 10.1371/journal.pone.0069389.g004
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Figure 5.  Nuclear-cytoplasmic shuttling is involved in p16-induced cell migration.  (A) Immunofluorescent detection of sub-
cellular localization of p16 proteins. p16-NES, p16 tagged with NES at the C-terminus; p16-2NES, p16 tagged with NES at both N-
and C-termini; p16-NLS, p16 tagged with NLS at the C-terminus; p16-2NLS, p16 tagged with NLS at both N- and C-termini. (B)
Immunoblot detection of p16 proteins tagged with NES or NLS sequences. β-actin serves as a loading control. (C) IP-Western blot
confirming the ability of NES- or NLS-tagged p16 to bind to Cdk4 and Cdk6. (D) Migration activity of MM189 cells expressing NES-
tagged p16 proteins. Bar, SEM. (E) Migration activity of MM189 cells expressing NLS-tagged p16 proteins. Bar, SEM. *, p<0.05; **,
p<0.01; ***, p<0.001.
doi: 10.1371/journal.pone.0069389.g005
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proteins involved in tumorigenesis including Notch and TGF-β
[35,36].
Consistent with previously published findings in other tumor
types in which p16 overexpression has been observed, our
immunostaining of an HCC tissue microarray demonstrated
that while most HCC samples were negative for p16 staining,
all of but one of the tumors with p16 immunoreactivity
displayed predominantly cytoplasmic staining, whereas other
tumor types on the array displayed a predominantly nuclear
staining pattern. Importantly, prior studies have indicated that
the presence of cytoplasmic p16 correlated with progressive
disease and poor prognosis [15,16,34]. However, we did not
identify a correlation between p16 levels and patient survival.
While the five-year survival rate was greater in p16-negative
HCC samples compared to the p16-positive samples included
on our TMA (35% vs. 31%), this difference was not significant.
Potentially, this result reflects the tissue samples selected for
inclusion on the TMA. Our experimental data on the impact of
p16 on HCC cell migration and lung colonization suggest that
p16 may impact HCC metastasis; however, the samples on the
Figure 6.  Enhanced Cdc42 and Rac1 activity in p16-expressing HCC cells.  (A) Immunoblot analysis of epithelial and
mesenchymal proteins and EMT-associated transcription factors in MM189 p16 and MM189 VC cells. BL185 cells and 3T3L1 cells
serve as positive controls for the expression of E-cadherin and vimentin, respectively. α-tubulin serves as a loading control. The
lower panel shows the quantification of 3 independent immunoblots. (B) Immunoblot detection of active Cdc42, Rac1, and Rho
proteins bound by GST-Pak1 and GST-Rhotekin. GTPγS serves as a positive control to maintain the active form of GTPase in the
reaction. Immunoblotting of whole cell lysate serves as an input control, and detection of GST serves as a loading control. (C) The
relative density of the bands corresponding to Cdc42, Rac1 and Rho in MM189 p16 cells and control MM189 VC cells.
doi: 10.1371/journal.pone.0069389.g006
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Figure 7.  Cdc42 is required for p16-mediated migration.  Immunoblot analysis for knockdown of (A) Cdc42, (C) Rac1, and (E)
RhoA in MM189 p16 cells. Cells infected with a vector encoding an shRNA targeting GFP serve as a non-silencing control (pLKO-
GFP). α-tubulin serves as a loading control. Migration activity of cells with knockdown of (B) Cdc42, (D) Rac1, and (F) RhoA relative
to MM189 cells infected with a non-silencing control. Data are from a representative experiment performed in duplicate. Bar, SEM. *,
p<0.05; **, p<0.01; ***, p<0.001.
doi: 10.1371/journal.pone.0069389.g007
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TMA were all obtained from patients who underwent surgical
resection, and therefore by definition did not have documented
disseminated disease at the time of surgery. Future analysis of
metastatic samples may yield a correlation with p16
expression.
INK4A is frequently inactivated by a variety of mechanisms in
HCC illustrating its role as a tumor suppressor in this
malignancy [5,6]. Interestingly, p16 was previously shown to
inhibit the migration and invasion of breast cancer and other
cells in a manner dependent on its interaction with Cdk6
[37–39]. In these prior studies, the ectopic p16 was
predominantly localized to the nucleus, whereas in HCC cells
ectopic p16 appears to be primarily cytoplasmic, consistent
with our immunostaining data of HCC samples. Here, by
contrast, we demonstrated that p16 is a positive regulator of
HCC cell migration – ectopic expression of p16 enhances cell
migration, whereas RNAi-mediated knockdown of p16 inhibits
this phenotype. Importantly, these results are reproducible in
multiple HCC and hepatoma cell lines of human and mouse
origin, demonstrating the significance of these findings.
Significantly, we find that increased p16 expression restricts
HCC cell proliferation in a pRb-dependent manner, and that
p16 inhibits other transformation-associated phenotypes, such
as soft agar colony formation, consistent with its known tumor
suppressor function. Thus, the effect of p16 on HCC cell
migration is specific, and likely does not reflect an experimental
artifact resulting from manipulation of p16 levels.
Interestingly, our data suggest that nuclear-cytoplasmic
shuttling of p16 may be involved in its regulation of cell
migration, as sequestration in either compartment impaired
p16-induced migration. How this shuttling occurs, and how it
impacts migration, remains unclear. In addition, p16-stimulated
cell migration is not affected by pRb expression status.
Moreover, the ability of p16 to regulate HCC cell migration
does not depend on regulation of Cdk4 and Cdk6 activity, and
p16 stimulates migration in cell lines in which it inhibits
anchorage-independent growth. Together, these data suggest
that p16 impacts cell migration via mechanisms independent of
those used to regulate cell cycle progression. What are these
mechanisms? Intriguingly, we found that ectopic p16
expression resulted in an increase in Cdc42 and Rac1
activation, along with a concomitant decrease in Rho activity.
Furthermore, RNAi-mediated inhibition of Cdc42 reduced, while
knockdown of RhoA enhanced, p16-induced cell migration.
Together, these findings suggest that regulation of Rho family
GTPases activity may be one mechanism.
In addition, mutation of the Cdk4-binding region of p16
demonstrated that this domain is required for its ability to
stimulate cell migration, suggesting that important mediators of
p16’s ability to induce cell migration also bind to this region of
the protein. Identifying these potential binding proteins is critical
to understanding the mechanism by which p16 stimulates cell
migration, and experiments are ongoing to address this issue.
Published work by Souza-Rodrigues et al has suggested that
p16 interacts with various actin and tubulin proteins [40].
However, these interactions were not validated in vivo, and it
remains to be determined whether these are true interactions,
or background identification of abundant cellular proteins by
mass spectrometry.
Of note, prior work from Roberts and colleagues identified a
similar pro-migration phenotype induced by another Cdk
inhibitor, p27 [41,42]. They additionally found that p27-induced
migration involved its interaction with the RhoA GTPase and
resulting inhibition of RhoA activation [41]. Our data suggest
that a similar mechanism may be at work with regards to p16-
induced cell migration as well. However, whereas a direct
interaction was observed between p27 and RhoA, we have
been unable to observe a direct interaction between p16 and
either Cdc42 or RhoA. Therefore it remains to be elucidated
whether the regulation of these GTPases downstream of p16
occurs via direct or indirect mechanisms.
Why might p16 stimulate cell migration, and in what
contexts? Proper organ and tissue development requires the
coordinated regulation of cell cycle exit, cellular differentiation,
and cell migration. Indeed, p27 has been shown to coordinately
regulate cell cycle exit and neuronal cell differentiation and
migration [42]. Thus, the pro-migratory effects of p16 may
reflect a previously undiscovered role in a similar process.
Tumors have likely co-opted this normal developmental
process – by expressing high levels of p16 in the cytosol, the
cell cycle arrest function of p16 is abrogated and the pro-
migratory effects of p16 are enhanced. Again, work on p27
provides supporting evidence as cytosol-sequestered p27
stimulates the migration of HepG2 cells [43,44]. However,
much needs to be done to understand p16-regulated cell
migration. Indeed, the ability of p16 to induce cell migration in
other tumor cell types in which cytoplasmic accumulation is
observed will need to be demonstrated, and the detailed
mechanisms that regulate this migration elucidated.
Nonetheless, the data presented herein demonstrate a novel
function of p16 and highlight the complexity regarding tumor
initiation and progression.
Supporting Information
File S1.  Supplementary methods.
(DOC)
Table S1.  PCR primers used in vector construction.
(DOCX)
Figure S1.  (A) Migration and invasion activity of low and high
passage MM189 cells expressing p16, and their vector
controls. Data are from representative experiments performed
in duplicate. Bar, SEM. (B) Immunoblot detection of pRb
expression (anti-Rb, sc-102, Santa Cruz) in MM189, BL322
and HepG2 cells. α-tubulin serves as a loading control. (C)
Immunoblot detection of pRb knockdown in HepG2 cells with
ectopic p16 expression (HepG2 p16). α-tubulin serves as a
loading control. (D) Migration activity of HepG2 cells with
ectopic p16 expression (HepG2 p16) following pRb
knockdown, relative to cells expressing a non-silencing control
(pLKO-GFP). Data are from a representative experiment
performed in duplicate. Bar, SEM. (E) Representative cell
proliferation assay for HepG2 with p16 ectopic expression
p16 Induces HCC Cell Migration
PLOS ONE | www.plosone.org 12 July 2013 | Volume 8 | Issue 7 | e69389
(HepG2 p16) and vector control (HepG2 VC). Bar, SEM. (F)
Representative soft agar assay for HepG2 cells with
knockdown of p16, as well as the non-silencing control. Bar,
SEM. *, p<0.05; **, p<0.01; ***, p<0.001.
(TIF)
Figure S2.  Immunohistochemical staining of paired HCC
tissue and normal liver demonstrates cytoplasmic localization
of p16 in the HCC specimen, but nuclear localization of p16 in
normal hepatocytes (denoted by arrows).
(TIF)
Figure S3.  (A) Immunofluorescent detection of p16 in BL185
cells infected with either vector control or retrovirus encoding
exogenous p16. (B) Leptomycin B (LMB) blocks the nuclear
export of p16. Immunofluorescent staining for p16 in MM189
p16 cells demonstrates nuclear and cytoplasmic localization in
untreated cells (left panel). Treatment with 5 nM LMB
(Sigma) for 12 hours (middle panel) or 24 hours (right panel)
results in nuclear accumulation.
(TIF)
Figure S4.  (A) Migration activity of MM189 cells with ectopic
p16 expression (MM189 p16) treated with Y27532
(Calbiochem), an inhibitor of RhoA. Data are from a
representative experiment performed in duplicate. Bar, SEM.
(B) Migration activity of MM189 cells with ectopic p16
expression (MM189 p16) treated with a Rac1 inhibitor
(Calbiochem). Data are from a representative experiment
performed in duplicate. Bar, SEM. *, p<0.05; **, p<0.01; ***,
p<0.001.
(TIF)
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